Evidence map›Paper›PMID 38024851›Full record

ArticleThe journal of allergy and clinical immunology. Global2023

Anupama Ravi, Eric V Marietta, Jeffrey A Alexander, Joseph A Murray, David A Katzka

Open access · goldAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Development and dysfunction of structural cells in eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2024
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Anupama RaviDivision of Pediatric Allergy, Mayo Clinic, Rochester.
Eric V MariettaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester.
Jeffrey A AlexanderDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester.
Joseph A MurrayDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester.
David A KatzkaDivision of Digestive and Liver Disease, Columbia University, New York.
Mayo Clinic in Arizona · USColumbia University · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with eosinophilic esophagitis (EoE) have a unique esophageal microbiome with increased presence of Objective: Microbiome-derived bacterial LPS activation of Toll-like receptors (TLR) is a potential mechanism for inducing inflammation in other chronic inflammatory diseases, but it has not been studied in EoE. Our aim was therefore to study microbiome-derived bacterial LPS activation of TLRs in EoE. Methods: We studied 10 patients with active EoE, 9 patients with inactive EoE, and 10 control patients. Esophageal biopsy samples from the controls, patients with active EoE (>15 eosinophils/hpf), and patients with inactive EoE were immunostained for the presence of Results: Conclusion: Esophageal microbiome-rich

Indexed as

Eosinophilic esophagitisesophagitisesophagusLPSmicrobiomeToll-like receptor

Identifiers

PMID38024851
PMCPMC10679775
OpenAlexW4384832373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.